

Technology Appraisal Committee Meeting (Committee C)

Minutes: Confirmed

Date and Time: Wednesday 18 January 2017, 10:00 – 17:30

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Professor Andrew Stevens (Chair) 2. Mr Kamal Balakrishnan 3. Mr Michael Chambers 4. David Chandler 5. Gail Coster 6. Dr Prithwiraj Das 7. Dr Nigel Langford 8. Professor Andrea Manca 9. Dr Iain Miller 10. Professor Eugene Milne (Vice Chair) 11. Professor Stephen O'Brien 12. Professor Andrew Renehan 13. Professor Matt Stevenson 14. Dr Paul Tappenden 15. Mr Robert Walton 16. Dr Judith Wardle	Present for all notes Present for 01 – 15 Present for all notes Present for 01 – 15 Present for all notes Present for all notes Present for all notes
-----------------	---	--

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Frances Sutcliffe	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Stephanie Yates	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Rebecca Hammersley	Administrator, National Institute for Health and Care Excellence	Present for all notes

Ross Dent	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 01 to 15
Nicola Hay	Technical Advisor, National Institute for Health and Care Excellence	Present for notes 01 to 15
Neil Hewitt	Technical Analyst National Institute for Health and Clinical Excellence	Present for notes 16 to 27
Richard Diaz	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 16 to 27

Non-public observers:

Dr Jill Colquitt	ERG Representative	Present for notes 01 – 12
Professor James Mason	ERG Representative	Present for notes 01 – 12
Hema Mistry	ERG Representative	Present for notes 01 – 12
Abdullah Pandor	ERG Representative	Present for notes 16 – 24
Professor Matt Stevenson	ERG Representative	Present for notes 16 – 24
Andrew Hunter	Patient Expert	Present for notes 01 – 12
Jonathan Pearce	Patient Expert	Present for notes 01 – 12
Dr George Follows	Clinical Expert	Present for notes 01 – 12
Sara Mulvanny	Patient Expert	Present for notes 16 – 24
David Ryner	Patient Expert	Present for notes 16 – 24
Prof Jane Apperley	Clinical Expert	Present for notes 16 – 24
Prof Oliver Ottmann	Clinical Expert	Present for notes 16 – 24
Jennifer Beveridge	NICE Observer	Present for all notes
Leslie Hayes	NICE Observer	Present for all notes
Lee Walker	NICE Observer	Present for all notes
Marie Harrisin gh	NICE Observer	Present for notes 16 – 28
Nicola Hay	NICE Observer	Present for notes 16 – 28
Albany Meikle	NICE Observer	Present for notes 16 – 28

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of venetoclax for treating chronic lymphocytic leukaemia and ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

The Chair informed the Committee of the non-public observers at this meeting: Jennifer Beveridge, Leslie Hayes, Lee Walker, Marie Harris and Albany Meikle.

2. Apologies were received from Professor Kathryn Abel and Dr Anna O'Neill

Any other Business

3. None.

Appraisal of venetoclax for treating chronic lymphocytic leukaemia [ID944]

Part 1 – Open session

4. The Chair welcomed the invited experts: Andrew Hunter, Jonathan Pearce and Dr George Follows, Dr Jill Colquitt, Professor James Mason and Hema Mistry to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from AbbVie to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
 - 6.1. Professor Andrew Renahan, David Chandler, Professor Eugene Milne, Gail Coster, Dr Iain Miller, Dr Judith Wardle, Mr Kamal Balakrishnan, Prof Matt Stevenson, Mr Michael Chambers, Dr Nigel Langford, Dr Paul Tappenden, Dr Peter Selby, and Robert Walton declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.
 - 6.2. Professor Andrea Manca declared a non-personal specific financial interest as co-investigator in two research grants relating to CLL (a NIHR PGfAR project and the recently funded EU IMI2 “HARMONY” project).
 - 6.2.1. It was agreed that this declaration would not prevent Professor Andrea Manca from participating in this section of the meeting.
 - 6.3. Professor Stephen O’Brien declared a non-specific non-personal financial interest as a member of the NCRI Haem Onc Clinical Studies Group.
 - 6.3.1. It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.
7. The Chair asked all NICE Staff to declare any relevant interests.
 - 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.

8. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.
 - 8.1. Andrew Hunter and Jonathan Pearce declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of venetoclax for treating chronic lymphocytic leukaemia.
 - 8.2. Dr George Follows declared a non-specific personal financial interest as he has received funding from AbbVie, Janssen and Roche for involvement in advisory papers and to cover travel expenses.
 - 8.2.1. It was agreed that this declaration would not prevent Dr George Follows from participating in this section of the meeting.
9. The Chair introduced the lead team, Professor Matt Stevenson, Mr Iain Miller and Judith Wardle who gave presentations on the clinical effectiveness and cost effectiveness of venetoclax for treating chronic lymphocytic leukaemia.
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
11. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
12. The Chair then thanked the experts for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2a – Closed session

13. Discussion on confidential information continued with the company representatives present.
 - 13.1. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2b – Closed session

14. The Committee continued to discuss the clinical and cost effectiveness of venetoclax for treating chronic lymphocytic leukaemia.
 - 14.1. The committee decision was based on consensus.
15. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia [ID671]

Part 1 – Open session

16. The Vice-Chair (Eugene Milne) welcomed the invited experts: Professor Jane Apperley, Sara Mulvanny, Professor Oliver Ottmann, David Ryner, Abdullah Pandor and Matt Stevenson to the meeting and they introduced themselves to the Committee.
17. The Vice-Chair welcomed company representatives from Incyte Corporation to the meeting.
18. The Vice-Chair asked all Committee members to declare any relevant interests
 - 18.1. Professor Andrew Renahan, David Chandler, Gail Coster, Dr Iain Miller, Dr Judith Wardle, Mr Kamal Balakrishnan, Mr Michael Chambers, Dr Nigel Langford, Dr Peter Selby, Professor Andrew Stevens, and Robert Walton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia.
 - 18.2. Andrea Manca declared a non-personal specific financial interest as co-investigator in the EU IMI2 funded “HARMONY” project, which focuses on a number of haematological malignancies including ALL and CML.
 - 19.2.1 It was agreed that this declaration would not prevent Andrea Manca from participating in this section of the meeting.
 - 18.3. Paul Tappenden declared a non-personal specific financial interest he acted as an internal peer reviewer for the Evidence Review Group Report for this appraisal, but would not be named as an ERG member.
 - 19.3.1 It was agreed that this declaration would not prevent Paul Tappenden from participating in this section of the meeting.
 - 18.4. Professor Stephen O’Brien is conflicted and declared his organisation has received substantial research funding from Ariad and Bristol Myers Squibb for clinical trials in CML and his main research interest is CML.
19. The Vice-Chair asked all NICE Staff to declare any relevant interests.
 - 19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
20. The Vice-Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 20.1. Sara Mulvanny declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of

the technologies to be considered as part of the appraisal of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia.

20.2. Professor Jane Apperley declared a non-personal non-specific financial interest as her group have received payment for commercial studies in the disease area.

20.2.1. It was agreed that this declaration would not prevent Professor Jane Apperley from participating in this section of the meeting

20.3. Professor Oliver Ottmann declared a non-specific personal financial interest for involvement in various drug trials.

20.3.1. It was agreed that this declaration would not prevent Professor Oliver Ottmann from participating in this section of the meeting.

20.4. David Ryner declared a non-personal non-specific financial interest as the CML Support Group (a charity) regularly receives funding from industry.

20.4.1. It was agreed that this declaration would not prevent David Ryner from participating in this section of the meeting

21. The Vice-Chair introduced the lead team, Mr Kamal Balakrishnan, David Chandler and Dr Prithviraj Das and who gave presentations on the clinical effectiveness and cost effectiveness of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

22. The Vice-Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

23. The Vice-Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.

24. The Vice-Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

25. Discussion on confidential information continued. This information was supplied by the company.

26. The Committee continued to discuss the clinical and cost effectiveness of ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

26.1. The committee decision was based on consensus.

27. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

28. Wednesday 15 February 2017 09:30 – 17:30 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.